Adalimumab Expectations Revised In The Wake Of Amgen Launch
Analysts Outline Predictions And Weigh In On Key Questions Yet To Be Answered
• By David Wallace
Analysts expect AbbVie to retain the vast majority of volume share in 2023 • Source: Shutterstock 
